William Blair analyst Myles Minter initiated coverage of Alto Neuroscience with an Outperform rating. The analyst says the company has a “pipeline of multiple potential blockbuster assets.” The firm sees the stock’s current valuation as attractive “for a uniquely positioned neuroscience player” funded through clinical readouts over the next 12-16 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANRO: